SEC Form 4 · accession 0001140361-17-010370
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel K Spiegelman
Officer — EVP, Chief Financial Officer
Period of report
Feb 28, 2017
Accepted (ET)
Mar 2, 2017 · 6:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 28, 2017 | M | 30,000 | $63.10 | A | 60,347 | D | |
| Common StockF1,F2 | Feb 28, 2017 | S | 30,000 | $94.00 | D | 30,347 | D | |
| Common StockF1,F2 | Mar 1, 2017 | S | 5,000 | $94.50 | D | 25,347 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Common StockF1,F4,F3 | $63.10 | Feb 28, 2017 | M | 30,000 | D | Dec 4, 2014 | Jun 3, 2024 | Common Stock | 30,000 | 21,700 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan executed on November 16, 2016.
- F2All shares were sold at the same price.
- F3Original option grant vests 6/48ths on December 4, 2014, and 1/48th on the 4th day of every month thereafter.
- F4Reflects the number of stock options that remain outstanding from this specific stock grant following the reported transaction.